Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antithrombotic Secondary Prevention After Stroke.

Hans-Christoph Diener1, Peter Ringleb

  • 1*Department of Neurology, University of Essen, Hufelandstrasse 55, Essen 45122, Germany. h.deiner@uni.essen.de

Current Treatment Options in Neurology
|August 7, 2001
PubMed
Summary

Antiplatelet drugs significantly reduce stroke risk in TIA and ischemic stroke patients. Aspirin, dipyridamole, ticlopidine, and clopidogrel offer varying benefits and side effect profiles for secondary stroke prevention.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache.

Headache·2021
Same author

Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE): A Randomized, Controlled Trial.

Circulation·2021
Same author

Doubtful use of placebo following placebo in recent controlled trials of lasmiditan and ubrogepant for the treatment of migraine attacks.

Cephalalgia : an international journal of headache·2021
Same author

Changes in anticoagulant prescription patterns over time for patients with atrial fibrillation around the world.

Journal of arrhythmia·2021
Same author

MMW Fortschritte der Medizin·2021
Same author

COVID-19 Vaccine-Associated Cerebral Venous Thrombosis in Germany.

Annals of neurology·2021

Area of Science:

  • Neurology
  • Cardiology
  • Pharmacology

Background:

  • Transient ischemic attack (TIA) and ischemic stroke patients benefit from antiplatelet therapy.
  • Antiplatelet agents reduce stroke, myocardial infarction (MI), and vascular death risk.

Purpose of the Study:

  • To review the efficacy and safety of antiplatelet drugs for secondary stroke prevention.
  • To compare aspirin, dipyridamole, ticlopidine, and clopidogrel in stroke prevention.

Main Methods:

  • Review of clinical trials and guidelines on antiplatelet therapy for TIA and ischemic stroke.
  • Analysis of drug efficacy, side effect profiles, and optimal dosing.

Main Results:

  • Aspirin (50-325 mg) moderately reduces stroke, MI, and vascular death; low doses are better tolerated.

Related Experiment Videos

  • Aspirin plus dipyridamole is superior to aspirin alone for stroke prevention.
  • Clopidogrel offers a better safety profile than ticlopidine, which is reserved for aspirin-intolerant patients.

    • Conclusions:

    • Antiplatelet therapy is crucial for secondary stroke prevention.
    • Drug selection depends on patient tolerance, risk factors, and previous events.
    • Further research is needed for optimal management of patients already on aspirin or with recurrent events.